Literature DB >> 9895378

Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells.

J C Lee1, A M Cevallos, A Naeem, J E Lennard-Jones, M J Farthing.   

Abstract

BACKGROUND: Investigation of anti-colon antibodies may be simplified if a sensitive method and homogeneous source of antigen were available. AIMS: To examine the anti-colon antibody response using human colonic carcinoma cell lines as antigen.
SUBJECTS: Patients with inflammatory bowel disease and other gastrointestinal disorders and healthy controls were studied.
METHODS: Comparative enzyme linked immunosorbent assays (ELISAs) were performed to assess the value of whole Caco-2, HT-29, and LS-180 cells as antigen. The antigenic determinants of the immune response were characterised by western blot analysis.
RESULTS: Sera demonstrated immunoreactivity against each of the cell lines, but different epitopes were recognised. Applying whole Caco-2 cells as antigen in an ELISA, the prevalence of anti-colon antibodies was significantly greater in patients with ulcerative colitis (36%) than Crohn's disease (13%), other gastrointestinal disorders (13%) and healthy controls (0) (p<0. 05). The immune response was not associated with one predominant antigen.
CONCLUSIONS: Fixed whole cell ELISA is a simple and feasible method for studying the anti-colon antibody response. This response is non-specific, being directed against multiple antigens, and is likely to be an epiphenomenon of inflammatory bowel disease, more so for ulcerative colitis than Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9895378      PMCID: PMC1727366          DOI: 10.1136/gut.44.2.196

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  F Seibold; P Weber; R Klein; P A Berg; K H Wiedmann
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

2.  Autoantibodies to colonic cells and subcellular fractions in inflammatory bowel disease: do they exist?

Authors:  M Cantrell; T Prindiville; M E Gershwin
Journal:  J Autoimmun       Date:  1990-06       Impact factor: 7.094

3.  In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis.

Authors:  T Hibi; M Ohara; K Toda; A Hara; H Ogata; Y Iwao; N Watanabe; M Watanabe; Y Hamada; K Kobayashi
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

4.  The association of autoimmune disorders with inflammatory bowel disease.

Authors:  J A Snook; H J de Silva; D P Jewell
Journal:  Q J Med       Date:  1989-09

5.  High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives.

Authors:  C Fiocchi; J K Roche; W M Michener
Journal:  Ann Intern Med       Date:  1989-05-15       Impact factor: 25.391

6.  Circulating antibodies against human colonic extract enriched with a 40 kDa protein in patients with ulcerative colitis.

Authors:  F Takahasi; H S Shah; L S Wise; K M Das
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

7.  Fluorescent anti-colonic and E. coli antibodies in ulcerative colitis.

Authors:  H Marcussen
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

8.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

9.  Serum and tissue autoantibodies to colonic epithelium in ulcerative colitis.

Authors:  J A Snook; J R Lowes; K C Wu; J D Priddle; D P Jewell
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

10.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

View more
  3 in total

1.  Isolation and characterization of a novel short peptide associated with Crohn's disease.

Authors:  K Mitsuyama; M Niwa; J Masuda; K Kuwaki; H Yamasaki; H Takedatsu; T Kobayashi; M Sata
Journal:  Clin Exp Immunol       Date:  2011-07-28       Impact factor: 4.330

2.  Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study.

Authors:  Archana Thakur; Peter Littrup; Elyse N Paul; Barbara Adam; Lance K Heilbrun; Lawrence G Lum
Journal:  J Immunother       Date:  2011-06       Impact factor: 4.456

3.  In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.

Authors:  Archana Thakur; Oxana Norkina; Lawrence G Lum
Journal:  Cancer Immunol Immunother       Date:  2011-06-29       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.